Home › NDC Lookup › RxCUI directory › RxCUI 2461539

14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG... — RxCUI 2461539

RxNorm drug concept · Semantic branded drug
RxCUI 2461539 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2461539
Official name14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG/ML Injection [Inmazeb]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asInmazeb 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection; Inmazeb 241.7 MG / 241.7 MG / 241.7 MG in 14.5 ML Injection; Inmazeb (atoltivimab-ebgn 16.67 MG/ML / maftivimab-ebgn 16.67 MG/ML / odesivimab-ebgn 16.67 MG/ML) per 14.5 ML Injection; Inmazeb (atoltivimab-ebgn 241.7 MG / maftivimab-ebgn 241.7 MG / odesivimab-ebgn 241.7 MG) per 14.5 ML Injection
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG/ML Injection [Inmazeb] RxCUI 2461539

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 7

    The active substance itself — no strength, form, or brand attached yet.

    • Atoltivimab 2461338
    • Maftivimab 2461339
    • Odesivimab 2461340
    • Atoltivimab / maftivimab / odesivimab 2461538
    • Atoltivimab-ebgn 2461430
    • Maftivimab-ebgn 2461432
    • Odesivimab-ebgn 2461434
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Inmazeb 2461531
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atoltivimab / maftivimab / odesivimab Injection 2461437
    • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injection 2648862
    • Atoltivimab / maftivimab / odesivimab Injectable Product 2461436
    • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injectable Product 2659230
    • Atoltivimab / maftivimab / odesivimab Injection [Inmazeb] 2461532
    • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injection [Inmazeb] 2658009
    • Inmazeb Injectable Product 2461534
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 21 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG/ML Injection SCD · 2461536
  • Atoltivimab-ebgn 16.7 MG/ML SCDC · 2461431
  • Maftivimab-ebgn 16.7 MG/ML SCDC · 2461433
  • Odesivimab-ebgn 16.7 MG/ML SCDC · 2461435
  • Atoltivimab / maftivimab / odesivimab Injection SCDF · 2461437
  • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injection SCDFP · 2648862
  • Atoltivimab / maftivimab / odesivimab Injectable Product SCDG · 2461436
  • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injectable Product SCDGP · 2659230

Brand-Name Concepts

  • Atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG/ML [Inmazeb] SBDC · 2461537
  • Atoltivimab / maftivimab / odesivimab Injection [Inmazeb] SBDF · 2461532
  • Atoltivimab-ebgn / maftivimab-ebgn / odesivimab-ebgn Injection [Inmazeb] SBDFP · 2658009
  • Inmazeb Injectable Product SBDG · 2461534
  • Inmazeb BN · 2461531

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2461539 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61755-0018-01 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-018-01) / 14.5 mL in... Inmazeb Regeneron Pharmaceuticals, Inc. 2020-10-14
61755-0019-01 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-019-01) / 14.5 mL in... Inmazeb Regeneron Pharmaceuticals, Inc. 2021-07-29
Observed labelers: Regeneron Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.